Rejuran and Juvelook are both injections that place material into the skin. The choice turns on whether you look at skin texture first, or elasticity and volume loss first.
Rejuran is an injection of PN (sodium polynucleotide). The instructions for use state that it is used for temporary improvement of facial wrinkles in adults.
Juvelook is an injection of PDLLA (poly-D,L-lactic acid) plus non-cross-linked hyaluronic acid.
3-line summary
Rejuran is PN; Juvelook is PDLLA and hyaluronic acid. The injected materials are different.
Rejuran has human studies that looked at wrinkles, skin texture, and elasticity; Juvelook has data that looked at elasticity, hydration, and collagen tissue findings.
A schedule for placing both in the same site on the same day has not been set as a standard in the literature. Disclose pregnancy, infection, and medications first.
The injected materials are different
Both are given by injection, but the substance in the syringe is different. Comparison starts from what is injected. On the appointment day, the sites are confirmed then the injections proceed, and applying numbing cream first is common. Individual treatment information continues in the Rejuran treatment information and the Juvelook treatment information.
| Item | Rejuran | Juvelook |
|---|---|---|
| Material injected | PN | PDLLA + non-cross-linked hyaluronic acid |
| What human studies looked at | Wrinkles, skin texture, elasticity | Elasticity, hydration; collagen tissue findings |
| Common reactions | Redness, swelling, pain, itching; needle marks | Redness, swelling; needle marks |
| Additional questions | Whether it is Healer or HB | Whether it will be placed in thin sites such as under the eyes |
※ The table organizes the materials and the scope the literature examined. Dose and treatment order are confirmed against the product instructions on the day.
| What bothers you more now | Material to look at first |
|---|---|
| Skin texture, fine lines | Rejuran (PN) |
| Elasticity, volume loss | Juvelook (PDLLA + hyaluronic acid) |
| Both | Sequence and interval of the two materials are set separately |
Rejuran, an injection of PN
Experimental studies described PN as large molecular fragments obtained from fish DNA. Among those authors are people affiliated with related companies. Findings of increased collagen were reported in cells and animals, and measurements in people were done in a review of injections and a comparative study of the eye area.
A review that pooled PN injections reported changes in wrinkles, skin texture, and elasticity, and reactions were generally mild and short-lived. Among the authors is an education officer of a PN product distributor. There is a comparative study that placed Rejuran in wrinkles around the eyes. The original text of authorization, item classification, and contraindications is organized separately in the Rejuran Healer guide.
Needle marks, redness, and swelling are common through the day after injection. The instructions for use state to postpone makeup for 12 hours after treatment, and to avoid strong sunlight and saunas for 2 weeks afterward. Discomfort on the day can be checked in the Rejuran pain and recovery guide.
Juvelook, an injection of PDLLA and hyaluronic acid
PDLLA is a material that breaks down in the body, and the literature states that it stimulates collagen. Non-cross-linked hyaluronic acid is a material that holds water. Principle and process can be read further in the Juvelook complete guide.
In a preliminary study funded by the manufacturer, tissue findings of increased dermal collagen and elastic fibers were reported when additional hyaluronic acid was mixed into the Juvelook product. The schedule was divided across several sessions.
There is a case in which a firm nodule formed after Juvelook was placed under the eyes. A literature review lists nodules and granulomas as management issues for PDLLA. Thin sites and a response plan are covered in the Juvelook nodule guide.
Questions to read as written in the consultation room
Reading the following as written splits today's material and sites.
- □ Whether the name offered today is Rejuran Healer, HB, or Juvelook
- □ Whether to look at skin texture first, or elasticity and volume loss first
- □ Whether to place both materials in the same site on the same day, or leave an interval
- □ Whether there is a plan to inject thin sites such as under the eyes
- □ Pregnancy or breastfeeding, infection, autoimmunity, anticoagulants or immunosuppressants, fillers already placed
Cost varies with the amount injected and the number of sessions. Decision factors can be seen in the pricing information.
Frequently asked questions
Q1. Does it hurt?
Pain, swelling, itching, and redness at the injection site have been reported. Whether cream anesthesia is used is decided in the same-day explanation.
Q2. How many sessions?
Human PN studies included schedules of several sessions at 2-week intervals, and the Juvelook preliminary study placed it two or three times at 4-week intervals.
Q3. How long does it last?
The follow-up period of the comparative study that placed Rejuran around the eyes is 12 weeks. The instructions for use also describe it as temporary improvement. The Juvelook preliminary study looked at several weeks after treatment.
Q4. Can they be received together?
A schedule for placing both in the same site on the same day has not been set as a standard in the literature. Sequence and interval are decided after recovery is observed.
Q5. Who should postpone the schedule?
Items the Rejuran instructions for use list as contraindications are pregnancy or breastfeeding, minors, infected skin, autoimmune disease, anticoagulants or immunosuppressants, and sites that have received non-absorbable filler. Juvelook is also an injectable, so the same items are disclosed before treatment. Shared criteria are in the treatment safety information.
Results, duration, and suitability vary with individual skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.
Procedures may cause temporary redness or swelling, and contraindications may apply, so please confirm these during your consultation.
This article is general information and does not replace individual medical care. Please confirm diagnosis and treatment suited to your condition during a consultation.
Sources
- Lampridou S et al. (2025), J Cosmet Dermatol: The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review (PMID 39645667)
- Jeong GJ et al. (2020), J Cosmet Dermatol: A randomized, patient/evaluator-blinded, split-face study to compare the efficacy and safety of polycaprolactone and polynucleotide fillers in the correction of crow's feet: The latest biostimulatory dermal filler for crow's feet (PMID 31680395)
- Byun KA et al. (2025), Int J Mol Sci: Polynucleotides Enhance Collagen Synthesis via Modulating Phosphoenolpyruvate Carboxykinase 1 in Senescent Macrophages: Experimental Evidence (PMID 40943641)
- Lee KWA et al. (2024), Polymers (Basel): Poly-d,l-lactic Acid (PDLLA) Application in Dermatology: A Literature Review (PMID 39339047)
- Seo SB et al. (2024), J Cosmet Dermatol: Skin rejuvenation effect of the combined PDLLA and non cross-linked hyaluronic acid: A preliminary study (PMID 37969055)
- Seo SB et al. (2025), J Cosmet Dermatol: Energy-Based Device Management of Nodular Reaction Following Poly-D, L-Lactic Acid Injection for Tear Trough Rejuvenation (PMID 39283001)
Related reading
Discuss options for your current needs
We review your current health and prior procedures before explaining appropriate options and their limits.
